SynthesisPsychopharmacology2012
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.
Synthesis in Psychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.The international journal of neuropsychopharmacology · 2020Pooled it
- Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study.Psychopharmacology · 2024Trial
- Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).Psychopharmacology · 2022Trial
- Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Acute effects of THC on time perception in frequent and infrequent cannabis users.Psychopharmacology · 2013Trial
- Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Sex Differences in the Acute Effects of Oral THC: A Randomized, Placebo-Controlled, Crossover Human Laboratory Study.medRxiv : the preprint server for health sciences · 2024Article
- Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study.Iranian journal of pharmaceutical research : IJPR · 2021Review
- Cannabis vapor self-administration elicits sex- and dose-specific alterations in stress reactivity in rats.Neurobiology of stress · 2020Article
- Cannabis Extract Composition Determines Reinforcement in a Vapor Self-Administration Paradigm.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020Article
- Vaporized Cannabis Extracts Have Reinforcing Properties and Support Conditioned Drug-Seeking Behavior in Rats.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020Article
- Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans.Scientific reports · 2020Article
- Toward a Translationally Relevant Preclinical Model of Cannabis Use.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the "weed," a pharmacodynamic discussion.The mental health clinician · 2016Article
- The early identification of psychosis: can lessons be learnt from cardiac stress testing?Psychopharmacology · 2016Review
- Effects of Δ9-tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism.Psychopharmacology · 2014Article
- Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys.The Journal of pharmacology and experimental therapeutics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleDelta-9-tetrahydrocannabinol (THC) is one of the few cannabinoid receptor ligands that can be used to probe the cannabinoid system in humans. Despite increasing interest in the cannabinoid receptor system, use of intravenous THC as a research tool has been limited by concerns about its abuse liability and psychoactive effects.
objectivesThis study aims to evaluate the safety of all intravenous THC studies conducted at this center for the past 13 years.
methodsIncluded were 11 studies with 266 subjects (14 schizophrenia patients and 252 healthy subjects, of whom 76 were frequent cannabis users), 351 active THC infusions, and 226 placebo infusions. Subjects were monitored for subjective and physical adverse events and followed up to 12 months beyond study participation.
resultsThere was one serious and 70 minor adverse events in 9.7% of subjects and 7.4% of infusions, with 8.5% occurring after the end of the test day. Nausea and dizziness were the most frequent side effects. Adverse events were more likely to be associated with faster infusion rates (2-5 min) and higher doses (>2.1 mg/70 kg). Of 149 subjects on whom long-term follow-up data were gathered, 94% reported either no change or a reduction in their desire to use cannabis in the post-study period, 18% stated that their cannabis use decreased, and 3% stated that it increased in the post-study period.
conclusionsWith careful subject selection and screening, risk to subjects is relatively low. Safeguards are generally sufficient and effective, reducing both the duration and severity of adverse events.
Indexed as
Identifiers
21845389What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.